UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 516, 2009

Noven Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware	0-17254	59-2767632
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

11960 S.W. 144th Street, Miami, Florida		33186
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		305-253-5099

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

OnNoven ~~March 5~~Pharmaceuticals, ~~2009,~~Inc. ("Noven") ~~Pharmaceuticals~~today confirmed that Shire plc ("Shire"), ~~Inc.~~the ~~issued~~global alicensee ~~press~~of ~~release~~Daytrana® ~~announcing~~(methylphenidate transdermal system), has announced its ~~financial~~withdrawal ~~results~~of the European Marketing Authorization Application ("MAA") for Daytrana for the ~~year~~treatment ~~ended~~of ~~December~~Attention ~~31,~~Deficit ~~2008~~Hyperactivity Disorder ("ADHD"). ~~This~~Shire ~~press~~stated ~~release,~~that aits ~~copy~~decision ofto ~~which~~withdraw isthe ~~attached~~MAA ~~hereto~~was asbased ~~Exhibit~~on ~~99.1,~~the isfact ~~"furnished"~~that ~~and~~European ~~shall~~regulatory ~~not~~authorities behad ~~deemed~~requested ~~"filed"~~an additional clinical study for ~~purposes~~Daytrana ofin ~~Section~~a 18European ofpatient population, and that Shire planned to enter the ~~Securities~~European ~~Exchange~~ADHD ~~Act~~market through the previously-announced pending acquisition of ~~1934~~an ~~(the~~oral ~~"Exchange~~methylphenidate ~~Act")~~product orthat ~~incorporated~~is byalready ~~reference~~approved ~~into~~in aEurope. Noven ~~filing~~further ~~under~~confirmed ~~the~~that ~~Securities~~its ~~Act~~2009 offinancial ~~1933~~guidance in its Annual Report on Form 10-K, dated March 13, 2009 did not include any revenues or ~~the~~other ~~Exchange~~financial ~~Act~~contribution from European sales of Daytrana.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Noven Pharmaceuticals, Inc.
March 5, 2009	By:	/s/ Jeff Mihm
March 16, 2009	By:	/s/ Jeff Mihm
		Name: Jeff Mihm
		Title: Vice President, General Counsel and Corporate Secretary

Top of the Form

Exhibit Index

Exhibit No.		Description
99.1		Press Release, dated March 5, 2009, announcing Noven Pharmaceuticals, Inc.'s financial results for the year ended December 31, 2008.

Filing Compare · NOVEN PHARMACEUTICALS INC